Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07032597
PHASE3

A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants

Sponsor: AbbVie

View on ClinicalTrials.gov

Summary

The cumulative effect of aging and environmental exposures (ie, ultraviolet, infrared, and visible light radiation and pollution) leads to wrinkles, discoloration, laxity, and roughness of sun exposed skin. The rapid restoration of soft tissue augmentation is commonly achieved by the use of dermal fillers. HArmonyCa Lidocaine injectable gel is a dermal filler intended for facial soft tissue augmentation. The purpose of this study is to assess adverse events and effectiveness of HArmonyCa Lidocaine injectable gel compared to Restylane® Perlane® Lidocaine (Perlane) in adults seeking restoration and/or correction of moderate to severe mid-face volume deficit. HArmonyCa Lidocaine Injectable Gel is an investigational device being developed for soft tissue augmentation in the mid face. Participants are placed in 1 of 2 groups, called treatment arms. There is a 1 in 3 chance that participants will be assigned to the receive active comparator, Perlane. Around 252 adult participants seeking restoration and/or creation of mid-face volume will be enrolled in the study at approximately 9 sites in China. Participants will receive HArmonyCa Lidocaine injectable gel or Perlane at Day 1 with an option touch-up treatment on Day 31. Participants will be followed for up to 12 Months after last treatment. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Official title: A Multicenter, Evaluator Blinded, Randomized Study to Evaluate the Safety and Effectiveness of HArmonyCa Lidocaine Compared to Restylane® Perlane® Lidocaine for Restoration and/or Creation of Mid-face Volume

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

252

Start Date

2025-05-26

Completion Date

2026-10

Last Updated

2025-08-14

Healthy Volunteers

No

Interventions

DEVICE

HArmonyCa Lidocaine Injectable Gel

Subdermal or Deep Dermal or Supraperiosteal Injection

DEVICE

Restylane® Perlane® Lidocaine

Subcutaneous to Supraperiosteal Implantation Injection

Locations (9)

Beijing Hospital /ID# 272476

Beijing, Beijing Municipality, China

Peking Union Medical College Hospital (West) - Xidan Campus /ID# 272480

Beijing, Beijing Municipality, China

Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 272631

Wuhan, Hubei, China

Nanjing Drum Tower Hospital /ID# 272468

Nanjing, Jiangsu, China

Zhongda Hospital Southeast University /ID# 272471

Nanjing, Jiangsu, China

Wuxi People'S Hospital /ID# 275928

Wuxi, Jiangsu, China

Huashan Hospital Of Fudan University /ID# 272632

Shanghai, Shanghai Municipality, China

Shanghai Tongji Hospital /ID# 272509

Shanghai, Shanghai Municipality, China

The First People's Hospital of Hangzhou /ID# 272475

Hangzhou, Zhejiang, China